RiskBRCA Tests

Overview

BIOPROGNOS’ RiskBRCA Tests are innovative, non-invasive, accurate, cost-effective, already validated and CE certified tests for the determination of hereditary risk for Breast Cancer and Ovarian Cancer, through a simple saliva sample.

The RiskBRCA tests of BIOPROGNOS are:

Both RiskBRCA Basic and RiskBRCA Advanced are indicated to detect mainly BRCA1 and BRCA2 gene mutations. Besides, while RiskBRCA Basic only checks for all available SNPs for both BRCA1 and BRCA2, RiskBRCA Advanced also checks for further 7 gene mutations.

 
 

RiskBRCA BasicRiskBRCA Advanced
Checked Genes29
Genes ListBRCA1 & BRCA2ATM, BRCA1, BRCA2,
CDH1, CHEK2, PALB2,
PTEN, STK11 and TP53
SNPs CheckedWhole BRCA1 and BRCA2
gene mutations
Whole BRCA1 and BRCA2,
as well as other 7 gene mutations
related with hereditary
Breast and Ovarian Cancer
TechnologyNext Generation Sequencing (NGS)Next Generation Sequencing (NGS)

 
 

Breast and Ovarian Cancer Statistics

Every year more than 1,500,000 new cases of Breast Cancer and more than 240,000 of Ovarian Cancer are diagnosed worldwide, being hereditary between the 5-10% of Breast Cancer cases and approximately the 20% of Ovarian Cancer cases.

These cases of hereditary cancer are frequently associated with mutations in the BRCA1 and BRCA2 genes, both of which are tumor suppressor genes involved in the maintenance of DNA integrity.

What are BRCA1 and BRCA2?

BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help to repair the damaged DNA and, therefore, have the role of ensuring the stability of the genetic material of each of the cells.

When any of these genes have a mutation, or alteration, in such way that their protein is no longer produced or is not working properly, the DNA damage can not be repaired properly.

The specific mutations that are inherited in BRCA1 and in BRCA2 especially increase the risk of Breast and Ovarian Cancers in women.

In addition, women who have inherited mutations in BRCA1 and BRCA2 tend to have Breast and Ovarian Cancers at younger ages than those without these mutations.

History of BRCA1 and BRCA2

Clinical genetic testing of BRCA1 and BRCA2 began in the mid-1990s, but was mainly limited to one laboratory in the United States (US) and a small number of laboratories in Australia and Europe.

Twenty-five years later the number and types of patients being offered BRCA1 and BRCA2 testing has changed dramatically due in part to changes in patent laws and increased recognition of potential benefits of testing. Additionally, advances in highthroughput sequencing technology have enabled laboratories to offer less expensive tests than older ones and feature shorter turn-around times (TAT).

For whom are BRCA Tests intended?

  • Women with a family history of breast cancer (female or male) and/or ovary.
  • Women who suffer from breast or ovarian cancer to know their possible hereditary character.
  • Women over 30 years of age with no Breast or Ovarian Cancer family history, to know the genetic risk of hereditary Breast and Ovarian Cancer and be able to evaluate the different preventive and screening options.